Besides, combination therapies of mTOR inhibitors with other molecular-targeted therapies (EGFR, VEGFR, MEK, MAPK and MET) or conventional therapies may shed lights in HNSCC clinical success. Here, MTOR is linked to head and neck squamous cell carcinoma.